On June 2, 2023 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, reported that members of the Aclaris management team will participate in two healthcare investor conferences in June (Press release, Aclaris Therapeutics, JUN 2, 2023, View Source [SID1234632382]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will participate in a fireside chat during the 2023 Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 4:30 PM ET, in New York, NY.

Additionally, management will be participating in a fireside chat during the 44th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 14, 2023 at 4:40 PM PT/7:40 PM ET, in Dana Point, CA.

Webcasts of the fireside chats may be accessed through the "Events" page of the "Investors" section of Aclaris’ website, www.aclaristx.com. The webcasts will be archived for at least 30 days on the Aclaris website.

On Jume 1, 2023 GI Biome, an affiliate of GI Innovation and a microbiome drug development company, reported that it has started administering GB-X01 to the first patient in the domestic phase 1 clinical trial for colorectal cancer microbiome treatment (Press release, GI Biome, JUN 1, 2023, View Source [SID1234633251]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This clinical trial will be conducted at Samsung Seoul Hospital for patients who have completed standard treatment after radical resection of colorectal cancer. It is planned to evaluate the safety and tolerability of GB-X01 and to confirm changes in the composition of the intestinal microflora before and after administration. It is expected to secure phase 1 results in the second half of this year, including a 4-week dosing period for a total of 9 patients (up to 18) and a 4-week follow-up period thereafter. GB-X01

, obtained through GI Biome’s platform, has a single strain isolated from an adult female as its main component. As an oral drug, the antitumor effect was confirmed in monotherapy and combination therapy. It was said that ‘5-FU’, the most commonly used chemical anticancer drug for the treatment of colorectal cancer, showed a synergistic effect in combination with target anticancer drugs such as bevacizumab and natural killer (NK) cells under development by GI Cell . Based on these preclinical results, we applied for domestic and international patents on materials and uses. The company also confirmed through preclinical studies that it relieves anticancer drug-induced diarrhea ( CID ), which is a typical side effect of anticancer treatment, leading to treatment delay, dose reduction, and treatment discontinuation. A phase 2 plan for mitigating gastrointestinal side effects caused by the toxicity of chemical anticancer drugs is also taking shape.

When phase 1 is completed in the second half of this year, the goal is to apply for phase 2 in Korea early next year. In phase 2, it plans to evaluate the anticancer efficacy through the improvement of side effects caused by chemotherapy and the combination therapy of immune cell therapy.

On June 1, 2023 Triumvira Immunologics presented its corporate presentation (Presentation, Triumvira Immunologics, JUN 1, 2023, View Source [SID1234632480]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 2, 2023 Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to modulate the tumor microenvironment to elicit a potent and durable anti-tumor response, reported that Claire Mazumdar, Ph.D., MBA, Chief Executive Officer, will present at the 2023 Jefferies Global Healthcare Conference in New York, NY on Thursday, June 8, 2023 at 11:00 am ET (Press release, Bicara Therapeutics, JUN 1, 2023, View Source;utm_medium=rss&utm_campaign=bicara-therapeutics-to-present-at-the-2023-jefferies-global-healthcare-conference [SID1234632400]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 2, 2023 Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, reported that management will present at the following investor conferences in June (Press release, Immunocore, JUN 1, 2023, View Source [SID1234632391]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference
Fireside Chat: Wednesday, June 7, 2023, at 4:00 p.m. EDT
Goldman Sachs Annual Healthcare Conference
Fireside Chat: Wednesday, June 14, 2023, at 1:20 p.m. PDT
The presentations will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the events, a replay of the presentations will be made available for a limited time.